CRISPR Therapeutics AG logo

CRSP - CRISPR Therapeutics AG Share Price

$92.94 8.8  10.5%

Last Trade - 8:05pm

Sector
Healthcare
Size
Large Cap
Market Cap £4.61bn
Enterprise Value £3.89bn
Revenue £231.7m
Position in Universe 1018th / 6347
Bullish
Bearish
Unlock CRSP Revenue
Momentum
Relative Strength (%)
1m +39.5%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -1.05%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
0.000 0.25 5.16 41.0 3.12 289.6 16.9 16.6
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the three months ended 31 March 2020, Crispr Therapeutics AG revenues decreased 52% to $157K. Net loss increased 44% to $69.7M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Research and development - Balancing increase of 62% to $46.8M (expense), General and administrative - Balancin increase of 25% to $12.8M (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

CRSP Revenue Unlock CRSP Revenue

Net Income

CRSP Net Income Unlock CRSP Revenue

Normalised EPS

CRSP Normalised EPS Unlock CRSP Revenue

PE Ratio Range

CRSP PE Ratio Range Unlock CRSP Revenue

Dividend Yield Range

CRSP Dividend Yield Range Unlock CRSP Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
CRSP EPS Forecasts Unlock CRSP Revenue
Profile Summary

CRISPR Therapeutics AG is a Switzerland-based gene-editing company. It focuses on the development of transformative gene-based medicines for serious diseases. The Company develops its products using Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform, which allows for precise directed changes to genomic deoxyribonucleic acid (DNA). The Company has a portfolio of therapeutic programs in a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine and rare diseases. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from transfusion-dependent beta thalassemia or severe sickle cell disease in which a patient’s hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. The Company has business operations in London and the United Kingdom, as well as research and development operations in the United States.

Directors
Last Annual December 31st, 2019
Last Interim March 31st, 2020
Incorporated October 31, 2013
Public Since October 19, 2016
No. of Shareholders: 8
No. of Employees: 304
Sector Healthcare
Industry Biotechnology & Medical Research
Index Nasdaq Composite ,
Exchange NASDAQ Global Market
Shares in Issue 68,389,376
Free Float (0.0%)
Eligible for
ISAs
SIPPs
CRSP Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for CRSP
Upcoming Events for CRSP
Monday 27th July, 2020 Estimate
Q2 2020 CRISPR Therapeutics AG Earnings Release
Monday 26th October, 2020 Estimate
Q3 2020 CRISPR Therapeutics AG Earnings Release
Frequently Asked Questions for CRISPR Therapeutics AG
What is the CRISPR Therapeutics AG share price?

As of 8:05pm, shares in CRISPR Therapeutics AG are trading at $92.94, giving the company a market capitalisation of £4.61bn. This share price information is delayed by 15 minutes.

How has the CRISPR Therapeutics AG share price performed this year?

Shares in CRISPR Therapeutics AG are currently trading at $92.94 and the price has moved by 76.74% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the CRISPR Therapeutics AG price has moved by 68.04% over the past year.

What are the analyst and broker recommendations for CRISPR Therapeutics AG?

Of the analysts with advisory recommendations for CRISPR Therapeutics AG, there are there are currently 4 "buy" , 4 "hold" and 1 "sell" recommendations. The overall consensus recommendation for CRISPR Therapeutics AG is Hold. You can view the full broker recommendation list by unlocking its StockReport.

When will CRISPR Therapeutics AG next release its financial results?

CRISPR Therapeutics AG is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-03-31
What is the CRISPR Therapeutics AG dividend yield?

CRISPR Therapeutics AG does not currently pay a dividend.

Does CRISPR Therapeutics AG pay a dividend?

CRISPR Therapeutics AG does not currently pay a dividend.

When does CRISPR Therapeutics AG next pay dividends?

CRISPR Therapeutics AG does not currently pay a dividend.

How do I buy CRISPR Therapeutics AG shares?

To buy shares in CRISPR Therapeutics AG you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of CRISPR Therapeutics AG?

Shares in CRISPR Therapeutics AG are currently trading at $92.94, giving the company a market capitalisation of £4.61bn.

Where are CRISPR Therapeutics AG shares listed? Where are CRISPR Therapeutics AG shares listed?

Here are the trading details for CRISPR Therapeutics AG:

Country of listing: United States
Exchange: NMQ
Ticker Symbol: CRSP
What kind of share is CRISPR Therapeutics AG?

Based on an overall assessment of its quality, value and momentum, CRISPR Therapeutics AG is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a CRISPR Therapeutics AG share price forecast 2020?

Shares in CRISPR Therapeutics AG are currently priced at $92.94. At that level they are trading at 8.13% premium to the analyst consensus target price of 0.00.

Analysts covering CRISPR Therapeutics AG currently have a consensus Earnings Per Share (EPS) forecast of -4.599 for the next financial year.

How can I tell whether the CRISPR Therapeutics AG share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like CRISPR Therapeutics AG. Over the past six months, the relative strength of its shares against the market has been 40.73%. At the current price of $92.94, shares in CRISPR Therapeutics AG are trading at 53.18% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the CRISPR Therapeutics AG PE Ratio?

The CRISPR Therapeutics AG PE ratio based on its reported earnings over the past 12 months is 0.111k. The shares are currently trading at $92.94.

The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.

The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.

Who are the key directors of CRISPR Therapeutics AG?

CRISPR Therapeutics AG's management team is headed by:

Rodger Novak - CHM
Samarth Kulkarni - CEO
Bradley Bolzon - IND
Ali Behbahani - IND
Simeon George - IND
Tony Ho - EVP
James Kasinger - GCN
Michael Tomsicek - CFO
Lawrence Klein - COO
John Greene - IND
Katherine High - IND
Who are the major shareholders of CRISPR Therapeutics AG?

Here are the top five shareholders of CRISPR Therapeutics AG based on the size of their shareholding:

ARK Investment Management LLC Investment Advisor
Percentage owned: 7.02% (4.29m shares)
Versant Ventures Venture Capital
Percentage owned: 6.89% (4.21m shares)
Nikko Asset Management Americas, Inc. Investment Advisor/Hedge Fund
Percentage owned: 6.17% (3.77m shares)
GlaxoSmithKline PLC Corporation
Percentage owned: 5.35% (3.27m shares)
Nikko Asset Management Co., Ltd. Investment Advisor/Hedge Fund
Percentage owned: 5% (3.05m shares)
Similar to CRSP
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.